LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

LLY

1,136.75

-1.98%↓

JNJ

240.59

+1.09%↑

ABBV

227.54

+1.25%↑

UNH

408.27

+0.76%↑

MRK

119.2

-1.13%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

11.91 3.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.88

Max

12.1

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+164.88% upside

Dividenden
By Acuity
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-410M 938M
Vorige openingsprijs	8.88
Vorige sluitingsprijs	11.91

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

13 jun 2026, 23:52 UTC

China's House Price Index YoY release on June 16, 2026, faces cautious market sentiment amid ongoing declines and geopolitical tensions.

13 jun 2026, 23:51 UTC

Correlated Moves

Bitcoin has advanced since Friday, reflecting positive sentiment in the cryptocurrency market. The asset remains below its 20-day moving average and near its one-month range low.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Optimism Over U.S.-Iran Peace Talks, While Traders Anticipate Fed's Interest Rate Decision Amid Inflation Concerns.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism, Fed Expected to Hold Rates Amid Geopolitical Tensions and Key Economic Data Ahead.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on Peace Deal Optimism and Global Mineral Economy Shift Ahead of Steady Fed Rate Decision.

13 jun 2026, 23:41 UTC

U.S. Stocks Surge on SpaceX IPO and Peace Deal Hopes, While Investors Brace for Key Economic Data and Fed Rate Decision.

13 jun 2026, 23:41 UTC

Philadelphia Fed Manufacturing Index Release on June 18, 2026, Anticipates Growth Amid Mixed Economic Sentiment and Inflation Concerns.

13 jun 2026, 23:31 UTC

U.S. Industrial Production MoM data for May 2026 expected to rise by 0.2% amid cautious optimism following April's strong performance of 0.7%.

13 jun 2026, 23:21 UTC

U.S. Retail Sales MoM Report on June 17 Expected to Show Modest 0.5% Increase Amid Geopolitical Tensions and Consumer Spending Optimism

13 jun 2026, 23:21 UTC

U.S. Retail Sales Ex Autos Expected to Rise 0.5% in May Amid Cautious Consumer Sentiment and Economic Resilience

13 jun 2026, 23:21 UTC

Canada's New Housing Price Index set for June 17 release, with a forecasted slight decline amid ongoing affordability challenges and government announcements.

13 jun 2026, 23:11 UTC

Market Anticipates U.S. Building Permits Data Release Amid Cautious Optimism and Economic Concerns on June 16, 2026.

13 jun 2026, 23:02 UTC

India's RBI to release monetary policy meeting minutes amid lower-than-expected CPI inflation and rising food costs, influencing future interest rate decisions.

13 jun 2026, 23:02 UTC

Upcoming U.S. Housing Starts Data Release on June 16, 2026 Expected to Reflect Economic Conditions Amid Government Initiatives and Rising Demand.

13 jun 2026, 23:02 UTC

Investors Anticipate Further Increases in U.S. Export Prices Ahead of June 16 Release Amid Geopolitical Developments

13 jun 2026, 23:02 UTC

U.S. Housing Starts Expected to Reach 1.44 Million Units in May Amid Mixed Trends and Policy Discussions Ahead of June 16 Release

13 jun 2026, 23:02 UTC

U.S. Import Prices Report on June 16 Expected to Show 0.9% Increase Amid Geopolitical Optimism and Inflation Concerns

13 jun 2026, 23:02 UTC

Market Anticipates 1.41 Million Building Permits in May 2026 Amidst Cautious Optimism for Housing Sector Recovery.

13 jun 2026, 23:01 UTC

Macro News

DAX 30 Index rises in after-market trading amid optimism for a U.S.-Iran peace deal and President Trump's announcement on the Strait of Hormuz.

13 jun 2026, 22:51 UTC

Japan's Year-on-Year Inflation Rate Release on June 18 Expected to Show Stability Amid Mixed Economic Signals and Global Influences.

13 jun 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Hold at 1.4% Amid Cautious Market Sentiment and BOJ Policy Considerations

13 jun 2026, 22:41 UTC

Market anticipates June 15 release of NY Empire State Manufacturing Index at 13.2, signaling cautious optimism amid inflation concerns and geopolitical developments.

13 jun 2026, 22:41 UTC

Japan's Machinery Orders Expected to Rise 0.9% in April Amidst Mixed Economic Signals and Improving Investor Confidence

13 jun 2026, 22:41 UTC

Japan's Exports Expected to Rise 0.162% YoY in June Amid Positive Economic Sentiment and Geopolitical Easing, Despite Competition from China

13 jun 2026, 22:41 UTC

Mortgage Rates Set to Rise Amid Geopolitical Tensions and Economic Uncertainty, with Upcoming MBA Report Expected on June 17.

13 jun 2026, 22:32 UTC

UK Consumer Confidence Index for June 2026 Forecasted at -23 Amid Ongoing Inflation and Economic Uncertainty

13 jun 2026, 22:32 UTC

Canada's May 2026 Housing Starts Data Set for Release, Forecasted at 255K Units Amid Optimistic Market Sentiment and Government Initiatives.

13 jun 2026, 22:32 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on June 15, Amidst Cautious Market Sentiment and Global Economic Influences.

13 jun 2026, 22:32 UTC

Japan's trade deficit forecasted at -564.6 billion yen amid high import costs, but market optimism rises following easing U.S.-Iran tensions and strong Asian stock performance.

13 jun 2026, 22:32 UTC

Brazil's Retail Sales Report on June 16 Expected to Show Resilience Amid Mixed Economic Signals

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

164.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 164.88%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.